References
1. Stahl, M., et al., Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer, 2011.57 (4): p. 549-53.
2. Barker, L.M., et al., Survival after recurrence of Ewing’s sarcoma family of tumors. J Clin Oncol, 2005. 23 (19): p. 4354-62.
3. Bacci, G., et al., Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol, 2003. 14 (11): p. 1654-9.
4. Leavey, P.J., et al., Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children’s Oncology Group. Pediatr Blood Cancer, 2008. 51 (3): p. 334-8.
5. Lagmay, J.P., et al., Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children’s Cancer Group, Pediatric Oncology Group, and Children’s Oncology Group: Learning From the Past to Move Forward. J Clin Oncol, 2016. 34 (25): p. 3031-8.
6. Exelixis, Investigator’s Brochure for Cabozantinib (XL184).2015. Edition 11.0 .
7. Yakes, F.M., et al., Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011. 10 (12): p. 2298-308.
8. Fleuren, E.D., et al., Expression and clinical relevance of MET and ALK in Ewing sarcomas. Int J Cancer, 2013. 133 (2): p. 427-36.
9. Patane, S., et al., MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res, 2006. 66 (9): p. 4750-7.
10. Sampson, E.R., et al., The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res, 2011. 26 (6): p. 1283-94.
11. Chuk, M.K., et al., A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children’s Oncology Group. Pediatr Blood Cancer, 2018. 65 (8): p. e27077.
12. Italiano, A., et al., Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2020. 21 (3): p. 446-455.
13. Vo, K.T., K.K. Matthay, and S.G. DuBois, Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res, 2016.6 : p. 9.
14. Schiff, D., et al., Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer, 2016. 122 (4): p. 582-7.
15. Zhen, D.B., et al., A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Invest New Drugs, 2016.34 (6): p. 733-739.
16. Saylors, R.L., 3rd, et al., Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol, 1998.16 (3): p. 945-52.
17. Saylors, R.L., 3rd, et al., Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol, 2001. 19 (15): p. 3463-9.
18. Klega, K., et al., Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol, 2018. 2018 .
19. Kieuhoa T. Vo, J.G.M., Avanthi T. Shah, Joel M. Reid, Sarah A. Burhow, Eloise M. Graham, Fabienne Hollinger, Matthew A. Zapala, Janel Long-Boyle, Mi-Ok Kim, Katherine K. Matthay, and Steven G. DuBois,Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma. Journal of Clinical Oncology, 2020.
20. Michela Casanova, F.B., Quentin Campbell Hewson, Guy Makin, Lynley V. Marshall, Arnauld Verschuur, Adela Canete, Nadège Corradini, Bart Ploeger, Udo Mueller, Hong Zebger-Gong, John Woojune Chung, and Birgit Geoerger, Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors. Journal of Clinical Oncology, 2020(38).
21. Weiss, A.R., et al., Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol, 2020. 21 (8): p. 1110-1122.
22. Gaspar, N., et al., Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)(☆). ESMO Open, 2021. 6 (5): p. 100250.
23. McCabe, M., et al., Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). Journal of Clinical Oncology, 2022. 40 (17_suppl): p. LBA2-LBA2.